Benefits of exenatide on obesity and non‐alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes
Diabetes/Metabolism Research and Reviews2014Vol. 30(6), pp. 521–529
Citations Over TimeTop 10% of 2014 papers
Abstract
Exenatide has a better hepatic-protective effect than intensive insulin therapy and perhaps represents a unique option for adjunctive therapy for patients with obesity, non-alcoholic fatty liver disease with elevated liver enzymes and T2D.
Related Papers
- → Exenatide compared with long‐acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long‐Acting insulin (HEELA) study(2009)148 cited
- → Reduced Daily Risk of Glycemic Variability: Comparison of Exenatide with Insulin Glargine(2009)45 cited
- → Quantifying the effect of exenatide and insulin glargine on postprandial glucose excursions in patients with type 2 diabetes(2008)12 cited
- → PDB5 IMPROVED TREATMENT SATISFACTION IN PATIENTS WITH TYPE-2 DIABETES TREATED WITH EXENATIDE OR INSULIN GLARGINE(2005)1 cited
- → Clinical characteristics and outcomes in patients with type 2 diabetes adding insulin glargine to exenatide or exenatide to insulin glargine in a US managed care setting(2011)